Quick Answer
Aldeyra Therapeutics, Inc. reported Operating Income of -$35.27 million for fiscal year 2025.
Aldeyra Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$35.27M | +41.3% |
| 2024 | -$60.12M | -40.5% |
| 2023 | -$42.79M | +31.7% |
| 2022 | -$62.68M | -11.5% |
| 2021 | -$56.22M | -54.4% |
| 2020 | -$36.42M | +42.3% |
| 2019 | -$63.07M | -58.9% |
| 2018 | -$39.70M | -76.5% |
| 2017 | -$22.49M | -20.3% |
| 2016 | -$18.70M | -55.9% |
| 2015 | -$11.99M | -64.9% |
| 2014 | -$7.27M | -97.8% |
| 2013 | -$3.68M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$8.00M | +50.4% | +21.3% |
| June 30, 2025 | -$10.17M | +43.5% | +2.5% |
| March 31, 2025 | -$10.43M | -11.0% | +35.4% |
| September 30, 2024 | -$16.14M | -69.0% | +10.4% |
| June 30, 2024 | -$18.01M | -74.1% | -91.7% |
| March 31, 2024 | -$9.39M | +44.1% | +1.6% |
| September 30, 2023 | -$9.55M | +35.4% | +7.7% |
| June 30, 2023 | -$10.34M | +41.6% | +38.4% |
- Aldeyra Therapeutics, Inc. showed an increase of +41.3% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, Aldeyra Therapeutics, Inc.’s operating income has declined by 859.2% (from -$3.68 million to -$35.27 million).
- The most recent figure is from Aldeyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: